Ninlaro (Ixazomib)

Brand Name

Ninlaro

Generic Name

Ixazomib

View Brand Information

FDA approval date: November 20, 2015

Classification: Proteasome Inhibitor

Form: Capsule

What is Ninlaro (Ixazomib)?

NINLARO is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy. NINLARO is a proteasome inhibitor indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy. Limitations of Use : NINLARO is not recommended for use in the maintenance setting or in newly diagnosed multiple myeloma in combination with lenalidomide and dexamethasone outside of controlled clinical trials. Limitations of Use : NINLARO is not recommended for use in the maintenance setting or in newly diagnosed multiple myeloma in combination with lenalidomide and dexamethasone outside of controlled clinical trials [see Warnings and Precautions.

Approved To Treat

Multiple Myeloma

Top Global Experts

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Related Clinical Trials

A Phase 1/1a Study of Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for Relapsed/Refractory Light Chain Amyloidosis

Who is this study for: Patients with relapsed/refractory light chain amyloidosis

Enrollment Status: Recruiting

Publish Date: April 13, 2026

Intervention Type: Procedure, Drug

Study Drugs: Dexamethasone, Ixazomib Citrate, Venetoclax

Study Phase: Phase 1

Summary: This phase I/Ia trial finds the best dose and side effects of venetoclax given in combination with ixazomib citrate and dexamethasone in treating patients with light chain amyloidosis that has come back (relapsed) or does not respond to treatment (refractory) and who have an abnormal genetic change \[translocation t(11;14)\]. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2)...

A Phase 2 Trial of Ixazomib for Kaposi Sarcoma

Who is this study for: Patients with Kaposi sarcoma

Enrollment Status: Recruiting

Publish Date: February 27, 2026

Intervention Type: Other, Drug

Study Drug: Ixazomib Citrate

Study Phase: Phase 2

Summary: This phase II trial studies how well ixazomib works in treating patients with Kaposi sarcoma. Ixazomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Exploratory Study of Ixazomib in Combination With Reduced Dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma

Enrollment Status: Recruiting

Publish Date: January 05, 2026

Intervention Type: Drug

Study Phase: Phase 4

Summary: Ixazomib combined with low-dose lenalidomide(10mg) vs Ixazomib alone as maintenance regimen in patients with high-risk multiple myeloma after induction and consolidation of VRD-based regimen.

View All Clinical Trials

Related Latest Advances

Comparative Effectiveness of Pomalidomide-Based Regimens in Relapsed/Refractory Multiple Myeloma: A Multicenter Real-World Analysis in China.

Journal: Cancers

Published: February 25, 2026

"Et tu, Brute?" -A Case of Ixazomib-Induced Cancer Therapy-Related Cardiac Dysfunction.

Journal: Internal medicine (Tokyo, Japan)

Published: February 23, 2026

Screening of FDA-approved drugs using a recombinant Cedar virus to improve treatment options for Nipah virus infection.

Journal: The Journal of general virology

Published: February 06, 2026

View All Latest Advances